Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746897 · ClinicalTrials.gov registry record · Phase 1
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Hefei TG ImmunoPharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 2
- Study locations
NCT05746897: Recruiting Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Hefei TG ImmunoPharma Co..
NCT05746897 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by Hefei TG ImmunoPharma Co.. The registered enrollment target is 38 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05746897, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Hefei TG ImmunoPharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
Primary Outcome
The incidence of DLTs during the DLT assessment period.
Conditions Studied
Interventions
- DRUG Pembrolizumab injection
- DRUG NM1F Injection
Study Locations (2)
Texas
- NEXT Oncology, Dallas - Dallas
Virginia
- Next Oncology, Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
What NCT05746897 shows while recruiting
NCT05746897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab injection is the first listed.
NCT05746897 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05746897 about?
NCT05746897 is a clinical study titled "A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors". A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors
What is the current status of trial NCT05746897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2023-04-13. Estimated completion is 2027-09-30.
What conditions does trial NCT05746897 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Melanoma, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT05746897?
The interventions under investigation include: Pembrolizumab injection (DRUG), NM1F Injection (DRUG).
Who is sponsoring clinical trial NCT05746897?
This trial is sponsored by Hefei TG ImmunoPharma Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05746897 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05746897's enrollment target sits among peer trials
38 309th of 381 higher than 71 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI